Insurance coverage for emerging diabetes technologies: Payers’ perspective

3Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Advances in glucose monitoring and insulin delivery technologies have led to the development of innovative self-management tools, such as continuous glucose monitoring, automated insulin delivery systems, and smart connected insulin pens. Although the clinical advantages of today’s emerging diabetes technologies are well documented, the cost of integrating these tools into clinical practice must be considered to sustain the financial viability of both public and private insurers. Most clinicians are unfamiliar with the process the commercial insurers follow when making these decisions. This article reviews the key factors the insurers consider when determining eligibility criteria.

References Powered by Scopus

Assessing psychosocial distress in diabetes: Development of the Diabetes Distress Scale

1135Citations
N/AReaders
Get full text

Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections the diamond randomized clinical trial

918Citations
N/AReaders
Get full text

Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial

756Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Emerging landscape of continuous glucose monitoring

9Citations
N/AReaders
Get full text

Use of insulin pumps and closed-loop systems among people living with diabetes: A narrative review of clinical and cost-effectiveness to enable access to technology and meet the needs of payers

8Citations
N/AReaders
Get full text

Connected Pens or Smart Pens: Technology Needs Context

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Nolan, T., & Frazzitta, M. (2021, September 1). Insurance coverage for emerging diabetes technologies: Payers’ perspective. Diabetes Technology and Therapeutics. Mary Ann Liebert Inc. https://doi.org/10.1089/dia.2021.0262

Readers over time

‘21‘22‘23‘240481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

60%

Environmental Science 1

20%

Nursing and Health Professions 1

20%

Save time finding and organizing research with Mendeley

Sign up for free
0